3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Dermatologic
1
Breast
1
Conditions
Melanoma
3
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Interventions
pembrolizumab
16
Cyclophosphamide
8
Nivolumab
7
Gemcitabine
6
Paclitaxel
5
Drug Therapy
5
Docetaxel
5
fludarabine
4
aldesleukin
4
Oxaliplatin
4
Fluorouracil
4
Carboplatin
4
ulixertinib
3
spartalizumab
3
Trastuzumab
3
Radiotherapy
3
Leucovorin
3
Capecitabine
3
trametinib
2
tovorafenib
2
pertuzumab
2
pegilodecakin
2
pazopanib
2
palbociclib
2
osimertinib
2
enzalutamide
2
cemiplimab
2
atezolizumab
2
Taxes
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Ramucirumab
×
Dermatologic
×
Clear all
NCT02791334
2024-09-27
PACT
Eli Lilly and Company
Phase 1
Completed
164 enrolled